Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial
Titel:
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial
Auteur:
Gadgeel, Shirish Hirsch, Fred R. Kerr, Keith Barlesi, Fabrice Park, Keunchil Rittmeyer, Achim Zou, Wei Bhatia, Namrata Koeppen, Hartmut Paul, Sarah M. Shames, David Yi, Jing Matheny, Christina Ballinger, Marcus McCleland, Mark Gandara, David R.